Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BCTX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Allogeneic GM-CSF-secreting Breast Cance | Breast Cancer | Phase 3 · NCT06072612 | Recruiting |
| BC1 cell line | Breast Cancer | Phase 1/2 · NCT06471673 | Unknown |
| Bria-OTS regimen and CPI (tislelizumab) | Breast Cancer | Phase 1/2 · NCT06471673 | Unknown |
Also used in these trials (approved or third-party drugs, not BCTX's own candidates): Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Interferon Inoculation, Recombinant Interferon Alfa-2b.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BCTX holds $22.8M in cash and short-term investments (as of Apr 30, 2026) and burns about $7.5M/quarter from operations, an estimated runway of 9.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 59 · Elevated
The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern.10-Q, Jun 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Marc Lustig Director, 10% owner · +902,935 options |
Insider | 2,542,935 | 29.23% | 2024-05-14 |
| Kenneth Griffin | Institution (13G, 5%+) | 717,198 | 8.24% | 2026-01-15 |
| Cable Car Capital, LP | Institution (13F) | 216,821 | 2.49% | 2026-06-30 |
| Sabby Management, LLC | Institution (13F) | 80,721 | 0.93% | 2026-06-30 |
| Iridian Asset Management LLC | Institution (13F) | 65,000 | 0.75% | 2026-06-30 |
| UBS Group AG | Institution (13F) | 43,642 | 0.50% | 2026-06-30 |
| HRT Financial LP | Institution (13F) | 34,904 | 0.40% | 2026-06-30 |
| Jane Street Group, LLC | Institution (13F) | 26,515 | 0.30% | 2026-06-30 |
| Luminarx Capital Management LP | Institution (13F) | 15,000 | 0.17% | 2026-06-30 |
| Plambeck Jeremy Myung Jae | 5%+ holder (13G) | 13,339 | 0.15% | 2025-08-25 |
| National Bank of Canada/FI/ | Institution (13F) | 1,803 | 0.02% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 1,033 | 0.01% | 2026-06-30 |
Share count 8,699,787 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →